The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Pancreatic cancer subtypes: a roadmap for precision medicine
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second cause of cancer-related deaths by 2020. Although it has traditionally been approached as a disease, accumulated evidences point to the clinical heterogeneity of this disease, which translate into disparity in outcomes among the patients. Much emphasis has been put into patient classification introducing a platform for more tailored therapies. In the last 10 years, there have been important advances in the understanding of the molecular pathogenesis of PDAC, which has culminated with a comprehensive integrated genomic analysis from RNA expression profiles. Bailey et al. defined four subtypes and the different transcriptional networks underlying them. Firstly, we briefly describe and compare different subtyping approaches, which are mostly based on tissue mRNA expression analysis. We propose that these latest approaches to disease classification embrace not only those patients that are surgically resectable (20%), but even patients ineligible for surgery. Such considerations will include possible reclassification of these specific subtypes, enabling more personalized diagnosis and individualized treatment. The ultimate goal of this review is to identify current challenges in this area and summarize current efforts in developing clinical modalities that can effectively identify these subtypes in order to advance Precision Medicine. KEY MESSAGES • Pancreatic cancer can no longer be considered as one disease. • The heterogeneity underlying pancreatic cancer patients makes therapeutic options based on one-size-fits-all approach ineffective. • Identifying patients that could benefit from a specific treatment would help to avoid futile therapy approaches and to improve outcomes and quality of life of those whose long-term survival is unpromising.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“primary tumors have been shown to undergo subtype switching in response to microenvironmental cues (Torres 2018)37.”
From Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution (2022) · cites this paper as Torres 2018
In the citing paper
“primary tumors have been shown to undergo subtype switching in response to microenvironmental cues (Torres 2018)37.”
From Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution (2022) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 2×
“Though the former has been somewhat evasive for pancreatic ductal adenocarcinoma cancer (PDAC), subtyping of this tumour has developed over the past 5 years, culminating in a Nature publication last year that provided genetic signatures for four basic molecular subtypes [1].”
BackgroundWhole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1×
“performed whole-genome sequencing and copy number variation analysis of 100 PDAC samples showing that variation in chromosomal structure is an important mechanism of DNA damage in pancreatic carcinogenesis and employed structural variation profiles to classify PDAC into four subtypes (stable, locally rearranged, scatt…”
BackgroundAllard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M. M., Amant, F. C., Biankin, A. V., Budínská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,797
Wang, Y.-D., Zhao, C.-Y., Wang, W., Shen, C., Lu, H., Zhang, L., Yu, W., Zhou, J., & Yan, W.-Z. (2012) · Hepatogastroenterology · doi:10.5754/hge12183 · Cited by 1,625
High-Throughput Sequencing Technologies
Reuter, J., Spacek, D. V., & Snyder, M. P. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.004 · Cited by 1,404
Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue
Gerdes, M. J., Sevinsky, C. J., Sood, A., Adak, S., Bello, M. O., Bordwell, A., Can, A. B., Corwin, A. D., Dinn, S. R., Filkins, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300136110 · Cited by 716
FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt
Pei, H., Li, L., Fridley, B. L., Jenkins, G. D., Kalari, K. R., Lingle, W., Petersen, G., Lou, Z., & Wang, L. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.07.016 · Cited by 709
The biology of circulating tumor cells
Pantel, K., & Speicher, M. R. (2015) · Oncogene · doi:10.1038/onc.2015.192 · Cited by 556
Badea, L., Herlea, V., Dima, S., Dumitraşcu, T., & Popescu, I. (2008) · PubMed · Cited by 531
An In vivo Platform for Translational Drug Development in Pancreatic Cancer
Rubio‐Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio–Donahue, C. A., Karikari, C. A., Shi, C., Danenberg, K. D., Danenberg, P. V., Kuramochi, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0113 · Cited by 422
Real-time Liquid Biopsy in Cancer Patients: Fact or Fiction?
Pantel, K., & Alix‐Panabières, C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2030 · Cited by 419
Imaging of colorectal adenocarcinoma using FT-IR microspectroscopy and cluster analysis
Lasch, P., Haensch, W., Naumann, D., & Diem, M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2003.12.006 · Cited by 405
Histology image analysis for carcinoma detection and grading
He, L., Long, L. R., Antani, S., & Thoma, G. R. (2012) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2011.12.007 · Cited by 404
Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501605112 · Cited by 398
Emerging strategies to effectively target autophagy in cancer
Rebecca, V. W., & Amaravadi, R. K. (2015) · Oncogene · doi:10.1038/onc.2015.99 · Cited by 290
A Compendium of Potential Biomarkers of Pancreatic Cancer
Gowda, H., Kandasamy, K., Ranganathan, P., Rani, S., Ramabadran, S., Gollapudi, S., Balakrishnan, L., Dwivedi, S. B., Telikicherla, D., Selvan, L. D. N., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000046 · Cited by 285
Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers
Kim, J., Bamlet, W. R., Oberg, A. L., Chaffee, K. G., Donahue, G., Cao, X.-J., Chari, S., Garcia, B. A., Petersen, G. M., & Zaret, K. S. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5583 · Cited by 269
Surgery for Recurrent Pancreatic Ductal Adenocarcinoma
Kleeff, J. H., Reiser–Erkan, C., Hinz, U., Bachmann, J., Debus, J., Jaeger, D., Friess, H., & Büchler, M. W. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000245845.06772.7d · Cited by 247
Philip, P. A., Mooney, M., Jaffe, D., Eckhardt, G., Moore, M. J., Meropol, N. J., Emens, L. A., O'Reilly, E. M., Korc, M., Ellis, L. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9022 · Cited by 240
Fehm, T. N., Hoffmann, O., Aktas, B., Becker, S., Solomayer, E. F., Wallwiener, D. R., Kimmig, R., & Kasimir‐Bauer, S. (2009) · Breast Cancer Research · doi:10.1186/bcr2349 · Cited by 238
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
Winter, J. M., Yeo, C. J., & Brody, J. R. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23192 · Cited by 234
Noll, E. M., Eisen, C., Stenzinger, A., Espinet, E., Muckenhuber, A., Klein, C., Vogel, V., Klaus, B., Nadler, W. M., Roesli, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4038 · Cited by 228
Sturgeon, C. M., Duffy, M. J., Hofmann, B. R., Lamerz, R., Fritsche, H. A., Gaarenstroom, K. N., Bonfrèr, J. M. G., Ecke, T., Grossman, H. B., Hayes, P. C., et al. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.133124 · Cited by 211
Hypermutation In Pancreatic Cancer
Humphris, J. L., Patch, A., Nones, K., Bailey, P. J., Johns, A. L., McKay, S., Chang, D. K.-F., Miller, D. K., Pajic, M., Kassahn, K. S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.060 · Cited by 209
Grützmann, R., Pilarsky, C. P., Ammerpohl, O., Lüttges, J., Böhme, A., Sipos, B., Foerder, M., Alldinger, I., Jahnke, B., Schackert, H. K., et al. (2004) · Neoplasia · doi:10.1593/neo.04295 · Cited by 198
Diagnosing breast cancer using Raman spectroscopy: prospective analysis
Haka, A. S., Volynskaya, Z. I., Gardecki, J. A., Nazemi, J., Shenk, R., Wang, N., Dasari, R. R., Fitzmaurice, M., & Feld, M. S. (2009) · Journal of Biomedical Optics · doi:10.1117/1.3247154 · Cited by 193
Knudsen, E. S., Vail, P. J., Balaji, U., Ngo, H., Botros, I. W., Makarov, V., Riaz, N., Balachandran, V. P., Leach, S. D., Thompson, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0162 · Cited by 190
Translating cancer genomes and transcriptomes for precision oncology
Roychowdhury, S., & Chinnaiyan, A. M. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21329 · Cited by 168
Fourier Transform Infrared Spectroscopy in Cancer Detection
Sahu, R., & Mordechai, S. (2005) · Future Oncology · doi:10.2217/14796694.1.5.635 · Cited by 129
Schlitter, A. M., Segler, A., Steiger, K., Michalski, C. W., Jäger, C., Konukiewitz, B., Pfarr, N., Endris, V., Bettstetter, M., Kong, B., et al. (2017) · Scientific Reports · doi:10.1038/srep41064 · Cited by 122
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma
Samuel, N., & Hudson, T. J. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.215 · Cited by 117
Riethdorf, S., Müller, V., Loibl, S., Nekljudova, V., Weber, K., Huober, J., Fehm, T. N., Schrader, I., Hilfrich, J., Holms, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0255 · Cited by 113
Survival in Pancreatic Carcinoma Based on Tumor Size
Agarwal, B., Correa, A. M., & Ho, L. (2008) · Pancreas · doi:10.1097/mpa.0b013e31814de421 · Cited by 102
Pancreatic cancer: Current research and future directions
Falasca, M., Kim, M., & Casari, I. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.01.001 · Cited by 101
Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
Kulemann, B., Rösch, S., Seifert, S., Timme, S., Bronsert, P., Seifert, G. J., Martini, V., Kuvendjiska, J., Glatz, T., Hussung, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04601-z · Cited by 96
Fiber-optic probes enable cancer detection with FTIR spectroscopy
Mackanos, M. A., & Contag, C. H. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.04.001 · Cited by 79
Demographics and Epidemiology of Pancreatic Cancer
Yeo, T. P., & Lowenfels, A. B. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182756803 · Cited by 78
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
Vaccaro, V. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i16.4788 · Cited by 63
Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian, M. J., & Brody, J. R. (2017) · PubMed · Cited by 45
Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling
Humphrey, E. S., Su, S., Nagrial, A. M., Hochgräfe, F., Pajic, M., Lehrbach, G. M., Parton, R. G., Yap, A. S., Horvath, L. G., Chang, D. K.-F., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.058313 · Cited by 40
Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?
Eason, K., & Sadanandam, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0141 · Cited by 33
Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma
Liu, H., Sun, B., Wang, S., Liu, C., Lu, Y., Ding, L., & Liu, X. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477481 · Cited by 33
Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic
Du, Y., Zhao, B., Liu, Z., Ren, X., Zhao, W., Li, Z., You, L., & Zhao, Y. (2017) · Journal of Cancer · doi:10.7150/jca.17622 · Cited by 32
Pancreatic cancer models for translational research
Behrens, D., Walther, W., & Fichtner, I. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.013 · Cited by 31
Balagurunathan, Y., Morse, D. L., Hostetter, G. H., Shanmugam, V., Stafford, P., Shack, S., Pearson, J. V., Trissal, M. C., Demeure, M. J., Hoff, D. D. V., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0402 · Cited by 26
Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models
DeCant, B. T., Principe, D. R., Guerra, C. E., di Magliano, M. P., & Grippo, P. J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00464 · Cited by 22
Self-citationAssociation between the spread of circulating tumor cells and breast cancer subtypes
Qi, X., Yang, X., Fan, L., Zhang, Y., Zhang, F., & Jiang, J. (2010) · Breast Cancer Research · doi:10.1186/bcr2582 · Cited by 7
Research works printed but not linked: 1
- Pantel K, 2015, Oncogene, 35, 1
Cited by
Sorted by citations
Zhou, D. C., Jayasinghe, R. G., Chen, S., Herndon, J. M., Iglesia, M. D., Navale, P., Wendl, M. C., Caravan, W., Sato, K., Storrs, E. P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01157-1 · Cited by 290
Orhan, A., Vogelsang, R. P., Andersen, M. B., Madsen, M. T., Hölmich, E. R., Raskov, H., & Gögenür, I. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.013 · Cited by 170
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Bannoura, S. F., Khan, H. Y., & Azmi, A. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1013902 · Cited by 122
Blasco, M. T., Navas, C., Martín-Serrano, G., Graña-Castro, O., Lechuga, C. G., Martín-Díaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.002 · Cited by 115
The Hippo Signaling Pathway in Pancreatic Cancer
Ansari, D., OHLSSON, H., Althini, C., Bauden, M. P., Zhou, Q., Hu, D., & Andersson, R. E. (2019) · Anticancer Research · doi:10.21873/anticanres.13474 · Cited by 104
Metadata
- Authors
- Torres, C., & Grippo, P. J.
- Affiliations
- University of Illinois Chicago (US)
- Corresponding author
- Torres, Carolina
- Venue
- Annals of Medicine
- Publisher
- Informa UK Limited
- Published
- 2018-03-22
- Volume
- 50
- Issue
- 4
- Pages
- 277-287
- ISSN
- 0785-3890 (ISSN-L)
- 1365-2060
- PMC
- PMC6151873
- OpenAlex
- W2793975714
- Cited by
- 104
- References
- 54
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 11 · 2023: 16 · 2022: 21 · 2021: 20 · 2020: 9 · 2019: 7 · 2018: 2
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (1R01CA161283)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- pancreatic ductal adenocarcinoma, tumor subtypes, molecular classification, precision medicine, RNA expression profiling, tumor heterogeneity, personalized treatment, resectability, unresectable pancreatic cancer
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Humans, Pancreas, Pancreatectomy, Pancreatic Neoplasms, Prognosis, RNA, Messenger, Biomarkers, Tumor, Treatment Outcome, Patient Selection, Drug Resistance, Neoplasm, Gene Expression Profiling, Carcinoma, Pancreatic Ductal, Genomics, Precision Medicine, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
